INVESTIGADORES
ALVAREZ Luis Ignacio
artículos
Título:
Albendazole treatment in cystic echinococcosis: pharmacokinetics and clinical efficacy of two different aqueous formulations
Autor/es:
CEBALLOS, L.; ELISSONDO, M.; MORENO, L.; SÁNCHEZ BRUNI, S.; DENEGRI, G.; ALVAREZ, L.; LANUSSE, C
Revista:
PARASITOLOGY RESEARCH
Editorial:
SPRINGER
Referencias:
Año: 2008 vol. 103 p. 355 - 362
ISSN:
0932-0113
Resumen:
Abstract
Albendazole (ABZ), a benzimidazole methylcarbamate
compound, is approved for the treatment of the echinococcosis cystic disease in
humans. The aim of the present work was to investigate the pharmacokinetic (PK)
behaviour and clinical efficacy of two different ABZ formulations on hydatid
cysts in infected mice. In the PK study, BalbC mice were orally treated with
either, an aqueous solution or an aqueous suspension of ABZ (50 µg/mL). Plasma
samples were collected between 0 and 16 h post-treatment and processed for
ABZ/metabolites quantification. The efficacy study involved two different
Experiments (1 and 2) where BalbC mice were artificially infected with Echinococcus granulosus protoscoleces
(1500 protoescoleces/animal). Eight months post-infection the animals were
allocated into three experimental groups: 1) Untreated control group, 2)
ABZ-solution treated group and 3) ABZ- suspension treated group. Each treated
group received ABZ (orally at 0.5 mg/kg) in two different treatment schemes: Experiment
1) every 48 h, during 30 days, Experiment 2) every 12 h, over 15 days. Mice were
sacrificed after treatments and whole cysts were recovered and weighed.
Transmission electron microscopy (TEM) was performed for cysts obtained from the
different experimental groups. A higher ABZ-sulphoxide (ABZSO) systemic
availability was observed in the animals treated with the ABZ aqueous solution
compared to those treated with the suspension. The administration of ABZ over
30 days every 48 h did not result in statistical differences on the weight of
the recovered cyst compared to untreated animals. However, both ABZ
formulations were highly effectives in mice treated during 15 days every 12 h.
The complementary information on ABZ kinetic disposition in infected mice and
its clinical efficacy using different formulations and dosage regimens may
contribute to identify improved chemical control for the hydatid disease.